MichaelUrbanCallaghanMD

Pediatric Anemia and Red Blood Cell Hematology, Pediatric Coagulation Disorder Hematology, Pediatric Platelet Disorder Hematology

Associate Professor, Central Michigan School of Medicine

Dr. Callaghan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Michael Callaghan is a pediatric hematologist/oncologist in Detroit, MI and is affiliated with multiple hospitals in the area, including DMC - Children's Hospital of Michigan and DMC Harper University Hospital. He received his medical degree from Wayne State University School of Medicine and has been in practice 14 years. He is experienced in polycythemia vera, sickle-cell anemia, and pediatric coagulation disorders.

Children's Hospital of MichiganFellowship, Pediatric Hematology/Oncology, 2005 - 2009
Children's Hospital of MichiganResidency, Pediatrics, 2003 - 2005
Wayne State University School of MedicineClass of 2003

PubMed

440 citations
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
Johnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel, Claude Negrier, Markus Niggli
The New England Journal of Medicine. 2018-08-29
146 citations
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
Michael U. Callaghan, Claude Negrier, Ido Paz-Priel, Tiffany Chang, Sammy Chebon
Blood. 2020-12-10
15 citations
Large-scale analysis of UPR-mediated apoptosis in human cells.
Andrew M. Fribley, Justin R. Miller, Tyler E. Reist, Michael U. Callaghan, Randal J. Kaufman
Methods in Enzymology. 2011-01-01

Journal Articles

Emicizumab Prophylaxis in Patients Who Have Hemophilia A Without Inhibitors
Christine Kempton, Gallia G Levy, Michael U Callaghan, The New England Journal of Medicine

Abstracts/Posters

Studying the Role of ETV6 in Megakaryopoiesis and Thrombopoiesis Using a Novel CRISPR-Cas9 Halotag Genome Editing Strategy
Michael Callaghan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Spontaneous Bleeding and Poor Bleeding Response with Extended Half-Life Factor IX Products: A Survey of Select US and Canadian Hemophilia Treatment Centers
Michael Callaghan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Germline Mutations in ETV6 are Associated with In Vivo cytoplasmic Localization of ETV6 and Cause Transcriptional Dysregulation of Interferon Response Genes
Michael Callaghan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Advances in Hemophilia A: Expert Guidance and Practical Case Discussions
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Longitudinal Study to Identify and Assess Adhesion Indices during Vaso-Occlusive Crises in Adults and Adolescents with Sickle Cell Disease
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Longitudinal Evaluation of a Standardized P-Selectin Flow Adhesion Bioassay: Potential Role for the Assessment and Prediction of Vaso-Occlusive Episodes in Sickle Cell...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

UniQure Offers a Closer Look at the Leading Hemophilia B Gene TherapyDecember 8th, 2020